{"name": "AMAG Pharmaceuticals",
 "permalink": "amag-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/amag-pharmaceuticals",
 "homepage_url": "http://www.amagpharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contactus@amagpharma.com",
 "phone_number": "(617) 498\u00e2\u20ac\u201c3300",
 "description": "",
 "created_at": "Fri May 27 01:43:48 UTC 2011",
 "updated_at": "Sat Jun 23 02:25:04 UTC 2012",
 "overview": "\u003Cp\u003EAMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company manufactures and sells two approved products, Feraheme (ferumoxytol) Injection for intravenous (IV) and GastroMARK. On June 30, 2009, Feraheme was approved for marketing in the United States by the United States Food and Drug Administration (FDA), for use as an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[105,
       150],
      "assets/images/resized/0013/6661/136661v1-max-150x150.png"],
     [[117,
       166],
      "assets/images/resized/0013/6661/136661v1-max-250x250.png"],
     [[117,
       166],
      "assets/images/resized/0013/6661/136661v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Brian",
      "last_name": "J.G. Pereira",
      "permalink": "brian-j-g-pereira",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "100 Hayden Ave",
    "address2": "",
    "zip_code": "02421",
    "city": "Lexington",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "AMAG gets European approval, $15M milestone payment",
    "stoned_year": 2012,
    "stoned_month": 6,
    "stoned_day": 22,
    "source_url": "http://www.masshightech.com/stories/2012/06/18/daily55-AMAG-gets-European-approval-15M-milestone-payment.html",
    "source_text": "",
    "source_description": "AMAG gets European approval, $15M milestone payment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AMAG Pharmaceuticals",
      "permalink": "amag-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:AMAG"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}